1) Strategic Overview and Leadership Insights
- HCA Health reported a solid demand for services, with adjusted admissions growing 3% YoY, marking the 22nd consecutive quarter of volume growth.
- CEO Samuel N. Hazen emphasized the company's resilience and strategic initiatives, including digital transformation and network development, to enhance patient access and operational efficiency.
- The leadership remains optimistic about the company's positioning despite challenges from federal policy changes and payer mix pressures.

2) Financial Performance and Segment Results
- Adjusted EBITDA was positively impacted by a $50 million benefit from Medicaid supplemental payment programs, with total expected benefits for 2026 now between $600 million and $800 million.
- Diluted earnings per share increased nearly 4% YoY, reflecting strong operational discipline and cost management.
- Key metrics for Q3 2026 include:
| Metric | Q3 2026 | Q3 2025 | YoY Change | |---------------------------|-----------|-----------|--------------| | Adjusted Admissions | 3% | 2.3% | ↑ | | ER Visits | 5.1% | - | ↑ | | Inpatient Surgeries | -1.4% | - | ↓ | | Outpatient Surgeries | -3.7% | - | ↓ |

3) Challenges and Headwinds
- The company faced a significant decline in exchange equivalent admissions, down 19% YoY, primarily due to patients losing coverage and migrating to uninsured status.
- The shift in payer mix is estimated to have negatively impacted adjusted EBITDA by approximately $400 million in Q3.
- HCA anticipates a continued impact from Medicaid supplemental payment reductions in 2027, expecting $550 million to $650 million less compared to 2026.

4) Operational Plans and Future Outlook
- For 2027, HCA expects service demand to remain strong, projecting volume growth of 2% to 3%.
- The company is focused on enhancing operational efficiency through its resiliency programs, which are expected to yield ongoing cost savings.
- Leadership is cautious about the surgical volume recovery, particularly in elective procedures, and will assess performance through Q4 before finalizing 2027 guidance.

5) Guidance and Investor Considerations
- HCA reaffirmed its guidance for 2026, indicating performance is expected to be in the upper half of previously set ranges.
- The company will provide more detailed guidance for 2027 in January, with key assumptions including stabilization in payer mix and no significant policy changes beyond current expectations.
- The call lacked specific numerical guidance on the impact of upcoming regulatory changes and their implications for future earnings.

Bottom line: HCA Healthcare is navigating through a challenging environment with strong operational performance and strategic initiatives in place. While facing headwinds from payer mix shifts and regulatory changes, the company remains optimistic about future growth and is well-positioned to deliver value to shareholders.